Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder
Drug: intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder

First Posted Date: 2006-10-23

Last Posted Date: 2018-03-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 379

Registration Number: NCT00391209

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Requena, Spain

Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Neoplasms
Peritoneal Neoplasm

Interventions: Drug: carboplatin
Drug: enzastaurin
Drug: placebo
Drug: paclitaxel

First Posted Date: 2006-10-23

Last Posted Date: 2020-10-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 153

Registration Number: NCT00391118

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain

Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: docetaxel

First Posted Date: 2006-10-23

Last Posted Date: 2011-04-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 211

Registration Number: NCT00391274

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wu Han, China

Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Phase 2

Completed

Conditions: Malignant Pleural Mesothelioma

First Posted Date: 2006-10-12

Last Posted Date: 2007-04-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT00386815

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Phase 2

Completed

Conditions: Benign Prostatic Hyperplasia

Interventions: Drug: Placebo
Drug: Tadalafil

First Posted Date: 2006-10-11

Last Posted Date: 2009-07-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 200

Registration Number: NCT00386009

Locations: 🇵🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto, Portugal

Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Phase 3

Completed

Conditions: Attention Deficit Disorder With Hyperactivity

First Posted Date: 2006-10-11

Last Posted Date: 2007-06-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 105

Registration Number: NCT00386581

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation

The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)

Phase 2

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2006-10-11

Last Posted Date: 2010-09-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 56

Registration Number: NCT00385944

Locations: 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France

An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain

Phase 4

Completed

Conditions: Diabetic Neuropathy, Painful

Interventions: Drug: duloxetine hydrochloride
Drug: pregabalin
Drug: gabapentin

First Posted Date: 2006-10-11

Last Posted Date: 2011-07-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 407

Registration Number: NCT00385671

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Siegen, Germany

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

Phase 2

Completed

Conditions: Severe Sepsis

Interventions: Drug: Drotrecogin alfa (activated)

First Posted Date: 2006-10-11

Last Posted Date: 2010-12-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 486

Registration Number: NCT00386425

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, West Midlands, United Kingdom

Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy

Phase 2

Completed

Conditions: Breast Neoplasms

First Posted Date: 2006-10-11

Last Posted Date: 2008-06-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 41

Registration Number: NCT00386087

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy